About this trial
Constipation is a common and debilitating non-motor symptom of Parkinson disease (PD) that often precedes the onset of classic motor symptoms by decades. There is no standardized algorithm for managing constipation in this patient population, nor are there dedicated treatments. Studies suggest that constipation can affect quality of life to a significant degree, in many cases just as much as motor symptoms. There is an unmet need for effective treatment options for constipation in this patient population. The goal of this study is to determine the efficacy and safety of pyridostigmine as a treatment for chronic constipation in patients with PD.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Be able to provide signed informed consent
Stated ability and willingness to comply with all study procedures
Able to take oral medications
Disqualifiers
Diagnosis of atypical parkinsonism
Diagnosis of drug-induced parkinsonism
Diagnosis of vascular parkinsonism
Known allergy to pyridostigmine bromide or other study drug components
Trial design
Treatments tested in this trial
- Pyridostigmine Bromide